Thyroid Artery Embolization for the Treatment of Compressive Goiters.

NCT07360587 | Recruiting

• 1 other identifier: 2025-5830
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.

Conditions

Thyroid Nodules

Keywords

Goiter; Thyroid Artery Embolization; thyroid nodule

Outcome Measures

Primary Outcomes (1)

• Change in Thyroid nodule volume

  TAE effectiveness to reduce overall thyroid and nodular volumes in benign compressive goiters assessing changes in Nodule(s) volume(s) and Thyroid lobe volume.

  Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.

Secondary Outcomes (4)

• Change in symptoms after TAE.

  Follow-ups at 3 months, 6 months and 12 months post-op.

• Safety level of TAE in compressive goiter: Adverse Events report

  Day of embolisation; Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.

• Safety level of TAE in compressive goiter: thyroid function tests

  At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.

• Safety level of TAE in compressive goiter: parathyroid function tests

  At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.

Study Arms (1)

Thyroid Artery Embolization

EXPERIMENTAL

Patients with diagnosis of Goiter with compressive symptoms in which other alternatives lack or are refused by the patient himself.

Procedure: Thyroid Artery Embolization

Interventions

Thyroid Artery Embolization PROCEDURE

Interruption of blood flow that supplies thyroid nodule using embolization technique.

Thyroid Artery Embolization

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
• Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
• TiRADS category 1, 2, 3 or 4 AND
• Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
• Patient at least 18 years old.

You may not qualify if:

• Comorbidities precluding endovascular procedure OR
• TiRADS category 5 OR
• Bethesda categories IV, V, VI on biopsy OR
• Refusal of the patient to participate OR
• Uncontrolled severe hyperthyroidism OR
• Minor patient.

Sponsors & Collaborators

• Université de Sherbrooke: lead

Study Sites (1)

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, J1H5H3, Canada

RECRUITING

Related Publications (11)

• Ramos HE, Braga-Basaria M, Haquin C, Mesa CO, Noronha Ld, Sandrini R, Carvalho Gde A, Graf H. Preoperative embolization of thyroid arteries in a patient with large multinodular goiter and papillary carcinoma. Thyroid. 2004 Nov;14(11):967-70. doi: 10.1089/thy.2004.14.967.

  PMID: 15671777 BACKGROUND

• Bonnici M, Nevin C, Boo S. Thyroid ima artery embolization for the treatment of Graves' disease and thyroid storm. Radiol Case Rep. 2023 May 28;18(8):2641-2644. doi: 10.1016/j.radcr.2023.04.044. eCollection 2023 Aug.

  PMID: 37273723 BACKGROUND

• Xiao H, Zhuang W, Wang S, Yu B, Chen G, Zhou M, Wong NC. Arterial embolization: a novel approach to thyroid ablative therapy for Graves' disease. J Clin Endocrinol Metab. 2002 Aug;87(8):3583-9. doi: 10.1210/jcem.87.8.8723.

  PMID: 12161479 BACKGROUND

• Galkin EV, Grakov BS, Protopopov AV. [First clinical experience of radio-endovascular functional thyroidectomy in the treatment of diffuse toxic goiter]. Vestn Rentgenol Radiol. 1994 May-Jun;(3):29-35. Russian.

  PMID: 7985368 BACKGROUND

• McDermott MT. Hyperthyroidism. Ann Intern Med. 2020 Apr 7;172(7):ITC49-ITC64. doi: 10.7326/AITC202004070.

  PMID: 32252086 BACKGROUND

• Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol. 2013 Apr;23(4):1044-9. doi: 10.1007/s00330-012-2671-3. Epub 2012 Oct 25.

  PMID: 23096937 BACKGROUND

• Guan SH, Wang H, Teng DK. Comparison of ultrasound-guided thermal ablation and conventional thyroidectomy for benign thyroid nodules: a systematic review and meta-analysis. Int J Hyperthermia. 2020;37(1):442-449. doi: 10.1080/02656736.2020.1758802.

  PMID: 32369708 BACKGROUND

• Papini E, Gugliemi R, Pacella CM. Laser, radiofrequency, and ethanol ablation for the management of thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2016 Oct;23(5):400-6. doi: 10.1097/MED.0000000000000282.

  PMID: 27504993 BACKGROUND

• Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.

  PMID: 26462967 BACKGROUND

• Khairy GA. Solitary thyroid nodule: the risk of cancer and the extent of surgical therapy. East Afr Med J. 2004 Sep;81(9):459-62. doi: 10.4314/eamj.v81i9.9221.

  PMID: 15626055 BACKGROUND

• Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009 Aug;39(8):699-706. doi: 10.1111/j.1365-2362.2009.02162.x.

  PMID: 19601965 BACKGROUND

MeSH Terms

Conditions

Thyroid Nodule; Goiter

Condition Hierarchy (Ancestors)

Thyroid Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Central Study Contacts

Laurent Fradet, MD FRCSC

CONTACT

+1-819-346-1110; Laurent.Fradet@USherbrooke.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: No needed.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, FRCSC

Model Details: This study is a prospective interventional cohort study. The prospective cohort setting allows us to evaluate the direct effect of TAE on a series of patients on a longer period and to strengthen the retrospective data previously documented in other studies. There is no comparative group in our study as it aims to prove that TAE is effective and safe in a "nonsurgical" population, a population in which other alternatives lack or are refused by the patient.

Study Record Dates

• First Submitted: December 2, 2025
• First Posted: January 22, 2026
• Study Start: January 31, 2026
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: January 22, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)